FrancescaCottiniMD

Hematologic Oncology

Assistant Professor, Division of Hematology

Dr. Cottini is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
400 W 12th Ave
Columbus, OH 43210
Phone+1 614-292-6818

Fax+1 614-293-7526

I am a hematologist who specializes in the treatment of patients with plasma cell disorders, such as multiple myeloma and amyloidosis. I completed my residency and hematology/medical oncology fellowship at The Ohio State University, where I became passionate about how the immune system affects myeloma growth, response to therapy and risk of infections.

My laboratory research combines Multiple Myeloma (MM) biology and immunology to focus on the identification and validation of novel therapeutical targets, while my clinical research aims at defining strategies to improve the safety of autologous stem cell transplant or anti-MM therapies.

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2017 - 2020
Ohio State University HospitalResidency, Internal Medicine, 2015 - 2017
Universita San RaffaeleClass of 2009, MD, Cum laude

AACR Scholar-in-Training Award American Association for Cancer Research, 2014, 2017
Young Fellow Award International Myeloma Foundation, 2015
TRTH participant EHA-ASH Translational Research Training in Hematology, 2014

PubMed

1 citations
CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma.
Aya Ismael, Allen J Robinette, Laila Huric, Jamie Schuetz, Kameron Dona
Leukemia. 2024-08-01
1 citations
CD56 expression predicts response to Daratumumab-based regimens.
Allen J Robinette, Laila Huric, Kameron Dona, Don Benson, Francesca Cottini
Blood Cancer Journal. 2024-04-12
2 citations
TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma.
Larissa Valle Guilhen Longo, Tiffany Hughes, Betina McNeil-Laidley, Francesca Cottini, Gerard Hilinski
Haematologica. 2024-02-01

Abstracts/Posters

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data
Francesca Cottini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018